Onxeo SA - Product Pipeline Review - 2015

Published: Dec, 2015 | Pages: 53 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Onxeo SA - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Onxeo SA - Product Pipeline Review - 2015', provides an overview of the Onxeo SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Onxeo SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Onxeo SA including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Onxeo SA's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Onxeo SA's pipeline products

Reasons to Buy

- Evaluate Onxeo SA's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Onxeo SA in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Onxeo SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Onxeo SA and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Onxeo SA
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Onxeo SA and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Onxeo SA Snapshot 5
Onxeo SA Overview 5
Key Information 5
Key Facts 5
Onxeo SA - Research and Development Overview 6
Key Therapeutic Areas 6
Onxeo SA - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Out-Licensed Products 11
Out-Licensed Products/Combination Treatment Modalities 12
Onxeo SA - Pipeline Products Glance 13
Onxeo SA - Late Stage Pipeline Products 13
Pre-Registration Products/Combination Treatment Modalities 13
Phase III Products/Combination Treatment Modalities 14
Onxeo SA - Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Phase I Products/Combination Treatment Modalities 16
Onxeo SA - Early Stage Pipeline Products 17
Preclinical Products/Combination Treatment Modalities 17
Discovery Products/Combination Treatment Modalities 18
Onxeo SA - Drug Profiles 19
acyclovir 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
doxorubicin 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
miconazole nitrate 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
belinostat 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
clonidine hydrochloride ER 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
BA-016 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
BA-026 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
irinotecan hydrochloride 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Onxeo SA - Pipeline Analysis 30
Onxeo SA - Pipeline Products by Target 30
Onxeo SA - Pipeline Products by Route of Administration 31
Onxeo SA - Pipeline Products by Molecule Type 32
Onxeo SA - Pipeline Products by Mechanism of Action 33
Onxeo SA - Recent Pipeline Updates 34
Onxeo SA - Dormant Projects 49
Onxeo SA - Discontinued Pipeline Products 50
Discontinued Pipeline Product Profiles 50
CHS-828 50
BA-032 50
Onxeo SA - Locations And Subsidiaries 51
Head Office 51
Other Locations & Subsidiaries 51
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 52
Disclaimer 53

List of Tables

Onxeo SA, Key Information 5
Onxeo SA, Key Facts 5
Onxeo SA - Pipeline by Indication, 2015 8
Onxeo SA - Pipeline by Stage of Development, 2015 9
Onxeo SA - Monotherapy Products in Pipeline, 2015 10
Onxeo SA - Out-Licensed Products in Pipeline, 2015 11
Onxeo SA - Out-Licensed Products/ Combination Treatment Modalities, 2015 12
Onxeo SA - Pre-Registration, 2015 13
Onxeo SA - Phase III, 2015 14
Onxeo SA - Phase II, 2015 15
Onxeo SA - Phase I, 2015 16
Onxeo SA - Preclinical, 2015 17
Onxeo SA - Discovery, 2015 18
Onxeo SA - Pipeline by Target, 2015 30
Onxeo SA - Pipeline by Route of Administration, 2015 31
Onxeo SA - Pipeline by Molecule Type, 2015 32
Onxeo SA - Pipeline Products by Mechanism of Action, 2015 33
Onxeo SA - Recent Pipeline Updates, 2015 34
Onxeo SA - Dormant Developmental Projects,2015 49
Onxeo SA - Discontinued Pipeline Products, 2015 50
Onxeo SA, Subsidiaries 51